Insulin glargine and lixisenatide study results released – No 68

Web Version

Forward

TABLE OF CONTENTS

•

Insulin glargine and lixisenatide study results released

•

Study shows Xultophy boosts glycaemic targets

•

Positive results from type 2 combination drug trial

•

Liraglutide delays progression of renal events

•

Ninjabetic – The love of learning

DO YOU HAVE A STORY TO TELL?

GET IN TOUCH

Email your diabetes stories to editor Oliver Jelley.

Join the expanding diabetes community on Twitter and follow us for the latest diabetes news updates at @DiabetesTimes.

DSN Spotlight – Maggie Shepherd

Maggie Shepherd has been in her position as an inpatient diabetes specialist nurse in Exeter for 21 years.

Read what she would like to see change in diabetes care and what her biggest career achievement has been so far. To read more, click here.

Honest debate – Dr Partha Kar’s latest blog post

It's nigh on impossible to have an honest debate about the NHS, isn't it?

Forget the politics. The funding, for a moment, it's rarely possible to do so within NHS circles. Now let's lay some cards on the table before anyone unfurls their indignant banners and views.

I have been asking for an honest debate about NHS for many, many moons. Go check my blogs over the last few years.

Heck, I have even been involved in asking for an honest cross-party commission to look at NHS funding, when many leaders were singing Hakuna Matata or running around a fire chanting Kumbaya, whilst waiting for the Holy Grail of leadership to land. To read more, click here.

NHS at stake as diabetes numbers soar

Tackling diabetes in England is "fundamental" to the future of the NHS, according to Public Health England (PHE).

The new Diabetes Prevalence Model, produced by the PHE National Cardiovascular Intelligence Network, states there are 3.8 million people thought to have both types of diabetes. To read more, click here.

Insulin glargine and lixisenatide study results released

A combination of insulin glargine and lixisenatide helps people with type 2 diabetes reach meal-time blood sugar targets, according to a new study.

The LixiLan-L trial investigated a fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide (iGlarLixi) in adults with type 2 diabetes. To read more, click here.

Study shows Xultophy boosts glycaemic targets

Adults with type 2 diabetes treated with Xultophy® (insulin degludec/liraglutide) are up to 4.5 times more likely to achieve glycaemic targets without hypoglycaemia and weight gain, research has suggested.

The Novo Nordisk trial compared two groups of type 2 diabetes patients uncontrolled on insulin glargine U100, treated with either insulin degludec/liraglutide or up-titrated insulin glargine U100. To read more, click here.

Positive results from type 2 combination drug trial

The combination of a GLP-1 receptor agonist and a SGLT-2 inhibitor has shown positive results in those with type 2 diabetes who do not respond to metformin.

The DURATION-8 trial showed Bydureon® (exenatide once-weekly) 2mg once weekly in combination with Forxiga® (dapagliflozin) 10mg once daily significantly reduced HbA1c. To read more, click here.

Liraglutide delays progression of renal events

The glucagonlike-peptide 2 (GLP-1) agonist liraglutide (Victoza) delays the progression of renal events, according to new research.

The findings, carried out by Novo Nordisk, found the drug particularly delayed the new-onset of persistent new- macroalbuminuria in people with type 2 diabetes. To read more, click here.

Ninjabetic – The love of learning

As I sat back on my sofa with a cup of tea in my hand, feet up and my day-to-day tasks behind me, I realised what a beautiful thing online learning is.

It’s fast, fun, easy to access and it suits my life. There I was refreshing my memory on the carb counting skills I had learned four years ago (which are now very rusty, I have to say!), from the comfort of my own home, with the option to take as long as I needed or to skip to another section as and when I was ready. To read more, click here.

DIABETES DIGEST

Southampton launches 'revolutionary' diabetes care

Healthcare professionals in Southampton are spearheading a pioneering blueprint which will revolutionise care for people with diabetes in hospitals.

Led by Dr Mayank Patel, a consultant in diabetes at University Hospital Southampton NHS Foundation Trust, the innovative scheme provides guidance for all medical and nursing staff on what steps are needed to meet patients’ needs.

To read more, click here.

Pre-eclampsia and diabetes link found

A link between pre-eclampsia in pregnancy and the development of diabetes in later life has been found in a new study.

The condition, which results in high blood pressure and protein in the mother’s urine, affects 5-8 per cent of pregnancies and is the most common cause of severe perinatal ill health.

The research, carried out by Keele University, showed that pre-eclampsia is independently associated with a two-fold increase in future diabetes.

To read more, click here.

Dieticians and diabetes nurses inspired

The next generation of diabetes leaders learned a new range of invaluable skills at a leadership programme staged at the Leicester Diabetes Centre (LDC).

More than 20 diabetes specialist nurses and dieticians attended the latest Tomorrow’s Leaders course on Thursday, September 15, and Friday, September 16.

To read more, click here.

Type 1 video resource website launches

A video resource website aimed to help young people and their families better manage their type 1 diabetes has been launched.

DigiBete has been created in partnership with the diabetes team at Leeds Children's Hospital.

To read more, click here.

Type 1 resource website launches

A website which aims to pull together all the resources and support for people with type 1 diabetes has been launched.

T1 Resources is a collection of useful links, websites and online communities which the founders say can help people manage their diabetes better.

To read more, click here.